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A B S T R A C T
Background: To examine the effects of pitavastatin on atherosclerotic plaque in Watanabe heritable
hyperlipidemic (WHHL) rabbits using serial in vivo tissue-characterizing intravascular ultrasound.
Methods: A total of 11 WHHL rabbits of 10–12 weeks of age were divided into two groups, control and
pitavastatin-administered groups. A total of 29 atherosclerotic plaque segments from control group and
43 plaque segments from the pitavastatin group were serially imaged by 40 MHz intravascular
ultrasound in vivo with a tissue characterization software (iMAPTM, Boston Scientiﬁc, Natick, MA, USA) at
the baseline and the follow-up (16th week).
Results: The level of low-density lipoprotein cholesterol was signiﬁcantly decreased in pitavastatin group.
During the follow-up period, plaque area was signiﬁcantly increased in the control group, whereas it was
not signiﬁcantly changed in the pitavastatin group. The ﬁbrotic, necrotic, and necrotic plus lipidic areas
were signiﬁcantly increased in the control group, while no signiﬁcant change was revealed for tissue proﬁle
in pitavastatin group. The change in the percent areas of ﬁbrotic and lipidic plus necrotic tissues were
signiﬁcantly different between the two groups especially in the superﬁcial half portion of plaque.
Conclusions: These data indicate that pitavastatin could attenuate atherosclerotic plaque formation and
that it could stabilize the plaque in WHHL rabbits. Considering the fact that these were observed even with a
high follow-up level of cholesterol, these data might come from the pleiotropic effects of pitavastatin.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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It has been established that lowering levels of low-density
lipoprotein cholesterol (LDL-C) with 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) inhibitors (statins) is effective against the
development of cardiovascular events [1–3]. As the mechanism for
the preventive effects, various phenomena have been reported
using postmortem as well as experimental studies using animals
[4,5]. Previous clinical multicenter studies using intravascular* Corresponding author at: Division of Cardiology, Department of Internal
Medicine, Nihon University School of Medicine, Tokyo 173-8610, Japan.
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0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsultrasound (IVUS) have revealed that statins can inhibit the
atherosclerotic forming process of plaque, and that it can even
reduce the plaque volume [5–8]. Furthermore, it has been proved
that statins can change tissue composition of plaques as a
stabilization from their vulnerability to rupture [9–13].
Evidence was obtained as a consequence of innovation in
intravascular imaging, including not only IVUS, but also coronary
angioscopy, optical coherence tomography, and so on. However,
human studies usually have a lot of confounding factors in the
statistics, and more genuine evidence would be necessary.
Therefore, experimental animal study is also important to prove
the net effect of statins on plaque characteristics. Previous studies
with animals included a qualitative postmortem histologic demon-
stration [14,15], or serial examinations using magnet resonance
imaging [16], positron-emission tomography [17], or gray-scale reserved.
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with color IVUS. We have successfully developed a way of
experimental study to be able to observe plaque change by serial
color IVUS in Watanabe heritable hyperlipidemic (WHHL) rabbits
[19], a model of human familial hypercholesterolemia, over
16 weeks.
Pitavastatin is a unique HMG-CoA reductase inhibitor with
powerful lipid-lowering effects. Its ability to lower LDL-C is
comparable to that of atorvastatin and it also enhances high-
density lipoprotein cholesterol (HDL-C) [20]. Previous human
studies have reported that pitavastatin can regress plaque volume
[5,12,21] as well as stabilize plaque tissue composition
[12,21]. Therefore, the purpose of the present study was to
investigate the effect of pitavastatin on tissue characteristics of
atherosclerotic plaque in WHHL rabbits using serial in vivo IVUS
studies, which included volume measurement of gray-scale
images and quantitative tissue characterization with color images
from a commercially available application (iMAPTM, Boston
Scientiﬁc, Natick, MA, USA).
Methods
Animal preparation and medication
Male and female homozygous WHHL-myocardial infarction
(WHHL-MI) rabbits (developed at Kobe University, Kobe, Japan)
were housed in a room at 22  2 8C temperature and 65  5%
humidity, illuminated from 08:00 h to 20:00 h. A total of 11 WHHL
rabbits were divided into 2 groups, control and pitavastatin groups.
These rabbits were all fed on 100 g/day of standard chow (CR-3; CEAR
Japan, Inc., Tokyo, Japan). Pitavastatin was synthesized and provided
by Kowa Co. Ltd, Aichi, Japan. Pitavastatin was orally administered at
concentration of 0.0006% (w/v) in the pitavastatin group. The
duration of treatment was 16 weeks beginning at 10–12 months of
age. The dosage of pitavastatin was determined according to the
previous studies that used it in WHHL rabbits [14]. At the IVUS
examination, the rabbits were anesthetized with 3% sevoﬂurane. To
endure this relatively long observation period for the rabbits after the
ﬁrst IVUS examination, meticulous monitorings about water balance
as well as infection were performed. Cefazolin sodium of 0.03 g/kg
was administered intramuscularly at the ﬁrst IVUS and 24 h later. In
addition, a drip infusion of extracellular saline solution of 200 mL/day
over the ﬁrst 24 h was also performed from the ﬁrst IVUS. All animal
experiments were performed with the approval of the Animal
Experiment Committee of Nihon University and conformed to the
Guide for the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No, 85-23, revised
2011).
Measurement of plasma lipid
Blood samples were collected from a sheath into femoral
artery after overnight fasting at the baseline and at the follow-up
period. Plasma concentration of total cholesterol level was
determined using a L-type Wako CHO-H (Wako Pure Chemical
Industries, Osaka, Japan), and that of triglyceride level was
measured using a L-type Wako TG-H (Wako Pure Chemical
Industries). Plasma lipoprotein fractions were separated and
determined for low-density lipoprotein (LDL-C) level using
Cholestest1LDL (SEKISUI MEDICAL, Tokyo, Japan) and HDL-C
level using Cholestest1N HDL.
IVUS procedure
IVUS was used to examine plaque volume, lumen volume,
vessel volume, and plaque tissue characteristics within thebrachiocephalic arterial segments at the baseline and at the
follow-up period of 16th week of treatment. IVUS imaging was
performed with a 2.5 F, 40 MHz imaging catheter (Atlantis SR
Pro2TM and iLabTM Ultrasound Imaging System, Boston Scientiﬁc).
The imaging catheter was inserted from femoral artery, and was
advanced into right common carotid artery. The transducer was
positioned to the brachiocephalic artery that was target vessel. The
transducer was withdrawn by a motorized pullback device at a
speed of 0.5 mm/s. The imagings used the same imaging system
with the same type of IVUS catheter for both the baseline and
follow-up examinations.
IVUS measurement
The target plaque was assessed by volumetric and tissue
characteristic analysis using QIvus-iMapTM Full Edition 2.0 (Medis
Associated BV, Leiden, Netherlands). A series of cross-sectional
images for every 0.5 mm-apart vessel slice was measured by
manual on-screen planimetry, which was used to trace the leading
edges of the luminal and external elastic membrane borders. The
tissue characterization was performed with the iLabTM system.
Radiofrequency (RF) signals from region of interest (ROI) were ﬁrst
obtained, and then an algorithm installed in iMAPTM system
characterized tissue components within the ROI using spectrum of
the RF signal. This tissue characterization is based on a neural
network-based learning algorithm for determination of RF
spectrum shape by comparing with a library of RF spectrum
which was obtained from pre-determined tissues [22]. In this
system, a database of 12 000 image ROIs of histologically
established types was used to design a pattern recognition
algorithm to predict the tissue of a given ROI by examining
similarity of the RF-spectrum against the database using 40 tissue
detector arrays, in which four types of tissue components were
identiﬁed, such as calciﬁed, ﬁbrotic, lipidic, and necrotic areas. In
the iMAP system, a tissue was deﬁned as ﬁbrous when it had no
distinct lipid core but had a ﬁbrocellular matrix with dense
collagen bands. A lipid core was deﬁned as a contiguous area of
lipid-containing foam cells, extracellular lipids, cholesterol crys-
tals, and lipid pool. A necrotic core was deﬁned as necrotizing
material [23]. The accuracy of the iMAP system for these tissue
characterizations was described in a previous paper [22]. For each
vessel cross-section, the area of each of these tissue components
was measured within total plaque area, and within the inner half
(superﬁcial half) and the outer half (deep half) of the plaque, which
were divided by a centerline of plaque thickness. The software of
QIvus-iMapTM Full Edition 2.0 can draw the centerline by a special
algorithm of mathematical dot-to-dot interpolation, in which each
dot is determined by visual inspection. The centerline was made by
connection among the middle points which were determined
along the radial axes from the gravity center of the lumen between
lumen-intima and media-adventitia borders. In this serial study,
the same cross-section was imaged referring to the positions of the
inlet and outlet of the brachiocephalic artery. In order to precisely
match the portion and strictly compare the area between the
baseline and the follow-up, IVUS image acquirement was
performed meticulously by equal longitudinal dividing of the
vessel between the inlet and the outlet cross sections with a
distinct image of bifurcation of the branching.
Statistical analysis
Data are presented as the mean  SD. The statistical analysis
was carried out using paired or unpaired t-tests. Difference with
p-values less than 0.05 were regarded as statistically signiﬁcant. The
software used in these analyses was JMP (SAS Institute Inc., Cary, NC,
USA).
Table 2
Serial changes in gray-scale IVUS parameters (SD).
Baseline Follow-up p value
(Baseline vs.
follow-up)
Control group
Vessel area (mm2) 16.35  4.50 15.90  3.49 0.618
Lumen area (mm2) 9.44  3.29 7.66  2.06 0.021
Plaque area (mm2) 6.91  2.04 8.25  1.99 0.007
Pitavastatin group
Vessel area (mm2) 16.09  3.35 14.56  2.34 <0.001
Lumen area (mm2) 8.21  1.80 6.97  1.97 <0.001
Plaque area (mm2) 7.88  2.07 7.59  2.00 0.185
IVUS, intravascular ultrasound. Values are mean  SD.
Table 3
Serial changes in color IVUS parameters (SD).
Baseline
(mm2)
Follow-up
(mm2)
p value
(Baseline vs.
follow-up)
Control group
Fibrotic 4.24  0.88 4.79  1.00 0.013
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Lipid proﬁle
Table 1 shows laboratory data both at the baseline and the
follow-up period. There was no difference in lipid proﬁle between
the two groups at the baseline. After treatment with pitavastatin,
plasma total cholesterol (T-CHO) and LDL-C were signiﬁcantly
reduced by 28.6% and 21.2%, respectively, while these values were
not signiﬁcantly changed in the control group. HDL-C and
triglyceride (TG) were not signiﬁcantly changed during the
follow-up period between the two groups.
Gray-scale IVUS data
Table 2 shows IVUS-derived vessel area, lumen area, and plaque
area for the two groups at the baseline and the follow-up period.
There were no signiﬁcant differences in these values between the
two groups at the baseline. Plaque area was signiﬁcantly increased
in the control group, however, it was not signiﬁcantly changed in
the pitavastatin group. Vessel area was not signiﬁcantly changed in
the control group, while it was signiﬁcantly decreased in theTable 1
Lipid proﬁle of the two groups (SD).
Control
group (n = 5)
Pitavastatin
group (n = 6)
p value
(Control group vs.
pitavastatin group)
T-CHO (mg/dl)
Baseline 871.0  225.6 1151.8  247.5 0.112
Follow-up 780.0  105.7 801.8  112.6 0.773
p value (baseline
vs. follow-up)
0.418 0.014
LDL-C (mg/dl)
Baseline 684.0  181.2 850.0  132.2 0.147
Follow-up 650.6  51.6 663.2  68.0 0.766
p value (baseline
vs. follow-up)
0.696 0.003
HDL-C (mg/dl)
Baseline 7.6  1.4 10.0  4.7 0.313
Follow-up 7.6  1.7 5.7  1.1 0.154
p value (baseline
vs. follow-up)
1.000 0.074
TG (mg/dl)
Baseline 252.8  78.8 164.2  72.1 0.112
Follow-up 171.8  110.6 158.8  51.0 0.773
p value (baseline
vs. follow-up)
0.292 0.878
T-CHO, total cholesterol; LDL-C, low-density lipoprotein-cholesterol; HDL-C,
high-density lipoprotein-cholesterol; TG, triglyceride. Values are mean  SD.
Fig. 1. Example iMAPTM images of the control group and the pitavastatin group. In these e
decreased in an example of the pitavastatin group. The percent content of necrotic area
group, whereas necrotic area was increased and ﬁbrous area was decreased in the exa
Lipidic 0.50  0.31 0.75  0.43 0.053
Necrotic 2.05  1.41 2.86  1.43 0.018
Lipidic + Necrotic 2.55  1.65 3.62  1.73 0.017
Calciﬁed 0.19  0.17 0.17  0.15 0.763
Pitavastatin group
Fibrotic 4.75  1.04 4.47  0.87 0.056
Lipidic 0.73  0.38 0.74  0.38 0.795
Necrotic 2.18  1.27 2.21  1.30 0.856
Lipidic + Necrotic 2.91  1.59 2.95  1.58 0.827
Calciﬁed 0.18  0.14 0.13  0.10 0.117
IVUS, intravascular ultrasound. Values are mean  SD.pitavastatin group. As a consequence, lumen area was signiﬁcantly
decreased in both groups.
Color IVUS data
Fig. 1 shows images of iMAPTM at the baseline and the follow-up
period for the two groups. In particular, necrotic area shown as
pinkish area was apparently increased in controls while it was
decreased in the pitavastatin group.
Table 3 shows the absolute area of each tissue component in the
two groups at the baseline and the follow-up period in the entire
layer of plaques. During the follow-up period, ﬁbrotic area, necrotic
area, and necrotic plus lipidic area were signiﬁcantly increased inxamples, plaque area was increased in an example of the control group, while it was
 was decreased and ﬁbrotic area was increased in the example of the pitavastatin
mple of the control group.
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tissue proﬁle in the pitavastatin group. In this study, we compared
nominal change in the percent area of each tissue component in
total plaque area as well as in superﬁcial half of plaque area during
the follow-up period (Figs. 2 and 3). There were no signiﬁcant
differences in the nominal change of the percent area for all typesFig. 3. Nominal change of % content of each tissue component within the superﬁcial half o
for ﬁbrotic, lipidic, lipidic plus necrotic, and calciﬁed areas between the two groups. D
Fig. 2. Nominal change of % content of each tissue component within total plaque. There w
control and pitavastatin groups. Data are expressed as mean  SD.of tissue component between control and pitavastatin groups in
the entire layer of the plaques (Fig. 2). However, in the superﬁcial
half portion of plaque, there were signiﬁcant differences in
nominal change of percent area of ﬁbrotic, lipidic, and lipidic plus
necrotic tissues (Fig. 3). In the control group, ﬁbrotic tissue tended
to decrease, whereas lipidic, lipidic plus necrotic, and calciﬁedf the plaque. There were signiﬁcant differences in nominal change of the percentage
ata are expressed as mean  SD.
as no difference in its nominal change for all types of tissue component between the
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ﬁbrotic tissue tended to increase, and lipidic, lipidic plus necrotic,
and calciﬁed areas tended to decrease. There were no signiﬁcant
correlations between the change in LDL-C level from baseline to
follow-up and the change in lipidic plus necrotic area in the
pitavastatin group both for the entire layer of plaque and for the
superﬁcial half of plaque (Fig. 4).
Discussion
The major ﬁndings of the present study using WHHL-MI rabbits
with a serial IVUS examination were that administration of
pitavastatin inhibited the progression of atherosclerotic plaque
area as well as necrotic and/or lipidic areas during the follow-up
period of 16 weeks, even with a high level of LDL-C. These features
were found particularly in the superﬁcial half of the plaque.
Therefore, it was suggested that pitavastatin not only attenuated
progression of atherosclerosis but also induced plaque stabilization
in WHHL rabbits. We believe that this would be the ﬁrst report
evaluating statin-induced changes in plaque amount and in its tissueFig. 4. Relationship between the change in low-density lipoprotein cholesterol (LDL-C
signiﬁcant correlations between these two values in the pitavastatin group both for thcomposition serially by IVUS in an experimental animal model,
which has less confounding factors compared to human studies.
It has been well established from multicenter human studies
that statins can induce regression of plaque volume [5,7,8]. In this
study, the plaque area did not decrease during the follow-up
period. This might be because the level of LDL-C was high at around
600–800 mg/dl, although the level was signiﬁcantly decreased by
pitavastatin. In human studies, plaque progression was observed
usually when the level of LDL-C was decreased to less than 100 mg/
dl by statin. It might rather be noteworthy that pitavastatin could
even attenuate the process of atherosclerosis at such a high level of
LDL-C.
In the present study, this remarkable feature of pitavastatin
even at high levels of LDL-C could be observed especially in its
stabilizing effect on plaque. In the pitavastatin group, the increase
in lipidic and/or necrotic area was signiﬁcantly inhibited especially
within the superﬁcial half of the plaque, while the ﬁbrotic area
signiﬁcantly increased around the superﬁcial area compared to the
control group. Furthermore, vessel area was signiﬁcantly de-
creased only in the pitavastatin group during the observation) level from the baseline and the change in lipidic + necrotic area. There were no
e entire layer of plaque (A) and for the superﬁcial half of plaque (B).
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plaque stabilization. These data support the previous human
studies on plaque stabilizing effects of statins [9,10,13,21,24].
Hattori et al. reported using integrated backscatter IVUS (IB-
IVUS) and optical coherence tomography that pitavastatin induces
an increase in ﬁbrous cap thickness and a decrease in lipid volume
within human coronary plaque [21]. Otagiri et al. reported with IB-
IVUS that use of rosuvastatin in patients with acute coronary
syndrome signiﬁcantly decreased lipid component of the plaque
[13]. Kawasaki et al. revealed with three-dimensional IB-IVUS that
lipid mass diminished from coronary plaque by administration of
statin [24]. Although we used iMAPTMwhich was different from IB-
IVUS in terms of imaging mechanism, similar ﬁndings were
obtained, because lipidic plus necrotic area in iMAPTM corresponds
to lipidic area in IB-IVUS according to the deﬁnition of each tissue
component in each system [25]. Hirayama et al. [9] as well as
Kodama et al. [10] reported similar results using coronary
angioscopy that yellow grade of plaque surface color was
decreased by statin. Therefore, our study would reconﬁrm these
facts that lipidic and/or necrotic area within coronary plaque tends
to decrease as an effect of statin especially at the superﬁcial layer of
the plaque. On the other hand, the ﬁbrous area within total plaque
area was increased in the control group, and was not changed in
the pitavastatin group during the follow-up period in our study,
which seemed to be inconsistent with previous studies that ﬁbrous
cap thickness was increased. However, ﬁbrous components can be
found not only in the superﬁcial cap zone in the plaque, but also in
total plaque area, because ﬁbrous tissue forms ﬁbrous cap as well
as the whole matrix of plaque. Therefore, the change in ﬁbrous area
is determined by which change is predominant. In our study,
measurement of ﬁbrous area was also performed in the superﬁcial
half of the plaque, suggesting that ﬁbrous cap thickness might be
increased in the pitavastatin group, but that it might be decreased
in the control group. Therefore, from these viewpoints our data on
the change in ﬁbrous area were not inconsistent with the previous
data. Considering the high level of LDL-C even at the follow-up
period, our data might show the pleiotropic effects of pitavastatin,
since there were no signiﬁcant correlations between the change in
LDL-C level and the change in lipidic + necrotic area during the
observation period within plaque.
It has been shown that pitavastatin has various pleiotropic
effects; it reduces the inﬂammatory response [26], improves
endothelial function [27], and increases thrombomodulin expres-
sion [28]. These features might be involved in the plaque
stabilization of our study, although we did not directly measure
these markers. Previous experimental animal studies have
suggested that various processes are involved in the plaque
attenuation or stabilization. HDL, the major endogenous mediator
of reverse lipid transport, enters plaque and takes cellular as well
as extracellular lipids [29]. It is estimated that some lipoprotein-
derived lipids become scarce enough to enable monocytes to leave
the plaque [30]. The emigration cells take with them their
intracellular lipids, and their potential for secretion of unhelpful
lipases, proteases, and tissue factor [31]. In addition, removal of
necrotic, debris, calciﬁcations and ﬁbrosis also occurs [32–35],
facilitated by new, normally functioning macrophages. Further-
more, some acceptor particles might play a role in the mobilization
of cholesterol [36]. In addition to these various mechanisms, it has
been demonstrated that renin-angiotensin system might also be
involved in the plaque regression [37].
Study limitations
First, the number of the rabbits examined was relatively small,
although the WHHL rabbits were raised with genetic uniformity.
Second, despite careful observation of water balance, the rabbitstended to have dehydration especially in the follow-up period, so
that the areas of lumen as well as vessel area might be
underestimated. Especially in the statistics for the relationship
between the change in LDL-C level and the change of tissue
components, the limitation of under-powered statistics should be
considered.
Conclusions
The present study using serial IVUS and histological examina-
tion with WHHL-MI rabbits revealed that pitavastatin attenuated
atherosclerotic plaque area, and that it induced plaque stabiliza-
tion as well as its anti-inﬂammatory change. These data would
provide more genuine evidence with a less-confounding animal
model regarding the mechanism of statin in its preventive and/or
regressive effect on atherosclerotic plaque.
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